David Baker, Vallon CEO
April 22, 2022 10:51 AM EDT
Financing
R&D

Mi­cro­cap biotech seeks a merg­er or new in­vest­ment af­ter PhI­II flop — shares soar

Max Gelman

Senior Editor

Rough­ly a month af­ter its lead AD­HD drug went up in flames, a mi­cro­cap biotech is fac­ing the mu­sic.

Tiny Val­lon Phar­ma­ceu­ti­cals put out a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times